Trial Profile

A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Target Engagement of ACI-24 in Adults With Down Syndrome

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACI 24 (Primary)
Indications Down syndrome
Focus Adverse reactions; Therapeutic Use

Most Recent Events

14 Oct 2021 Planned initiation date changed from 1 Oct 2020 to 1 Oct 2021.
14 Oct 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
02 Jun 2021 According to an AC Immune media release, the company is planning to file an Investigational New Drug (IND) application for ACI-24 by year-end, followed by an accelerated clinical development in Down syndrome-related AD, with start of Phase 2 as early as 2022/23.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com